Solitor 5 Special Precautions

Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with solifenacin succinate. If urinary tract infection is present, an appropriate antibacterial therapy should be started.
Solifenacin succinate should be used with caution in patients with: Clinically significant bladder outflow obstruction at risk of urinary retention.
Gastrointestinal obstructive disorders and decreased gastrointestinal motility.
Reduced renal function, doses of solifenacin succinate greater than 5 mg are not recommended in patients with severe renal function.
Reduced hepatic function, doses of solifenacin succinate greater than 5 mg are not recommended in patients with moderate hepatic impairment.
Hiatus hernia/gastro-esophageal reflux and/or who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate esophagitis.
Autonomic neuropathy.
Myasthenia Gravis.
QT prolongation and Torsade de Pointes have been observed in patients with risk factors, such as preexisting long QT syndrome and hypokalemia.
Angioedema with airway obstruction has been reported in some patients on solifenacin succinate. If angioedema occurs, solifenacin succinate should be discontinued and appropriate therapy and/or measures should be taken.
Anaphylactic reaction has been reported in some patients treated with solifenacin succinate. In patients who develop anaphylactic reactions, solifenacin succinate should be discontinued and appropriate therapy and/or measures should be taken.
Effects on Ability to Drive and Use Machines: Since solifenacin, like other anticholinergics may cause blurred vision, and, uncommonly, somnolence and fatigue, the ability to drive and use machines may be negatively affected.